Amgen's Weight Loss Drug Maridebart Cafraglutide Shows Promising Phase 3 Study Results

Amgen has announced an update on its ongoing clinical study of maridebart cafraglutide, a weight loss drug, in adults without Type 2 Diabetes. The Phase 3 study aims to prove the drug's effectiveness in reducing body weight compared to a placebo. If successful, the results could positively impact Amgen's stock performance and position the company competitively in the weight management pharmaceutical market. Further details are available on the ClinicalTrials portal.

Amgen Inc. (AMGN) has announced an update on its ongoing clinical study of maridebart cafraglutide, a potential weight loss drug, in adults without Type 2 Diabetes. The Phase 3 study, titled "A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight," aims to prove the drug's effectiveness in reducing body weight compared to a placebo [1].

The study, which began on March 12, 2025, and has its last update on July 30, 2025, is testing maridebart cafraglutide in various doses administered subcutaneously. The primary goal is to assess its effectiveness in weight reduction compared to a placebo. The study is randomized and follows a parallel assignment model, with participants and investigators blinded to the treatment or placebo assignment, ensuring unbiased results [1].

If the study shows significant efficacy in weight reduction, it could positively impact Amgen's stock performance and position the company competitively in the weight management pharmaceutical market. The study is ongoing, and further details are available on the ClinicalTrials portal.

References:
[1] https://www.tipranks.com/news/company-announcements/amgens-promising-phase-3-study-on-weight-loss-drug-maridebart-cafraglutide
[2] https://www.biospace.com/press-releases/4dmt-presents-positive-60-week-results-from-4d-150-spectra-clinical-trial-in-dme-and-regulatory-update